CONCLUSION: These findings highlight the importance of vigilant, personalized surveillance in patients with immune-mediated kidney diseases receiving prolonged rituximab therapy, particularly considering the potential risks of malignancies. Given the extended treatment duration, further prospective studies and controlled trials are essential to better understand these long-term effects, optimize monitoring strategies.
